ASP8825 phase II study-A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ASP8825 in patients with restless legs syndrome

Trial Profile

ASP8825 phase II study-A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ASP8825 in patients with restless legs syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2014

At a glance

  • Drugs Gabapentin enacarbil (Primary)
  • Indications Restless legs syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 20 Nov 2009 Based on the positive results of this trial, Astellas Pharma and XenoPort have submitted a new drug application to the Pharmaceuticals and Medical Device Agency (PMDA) in Japan for the treatment of restless legs syndrome with gabapentin enacarbil.
    • 10 Mar 2009 Actual end date reported by ClinicalTrials.gov.
    • 10 Mar 2009 Status changed from active, no longer recruiting to completed, as completed by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top